Literature DB >> 12210282

Investigation of Notch3 as a candidate gene for bipolar disorder using brain hyperintensities as an endophenotype.

Eileen P Ahearn1, Marcy C Speer, Y T Chen, David C Steffens, Frederick Cassidy, Susan Van Meter, James M Provenzale, Richard H Weisler, K Ranga Rama Krishnan.   

Abstract

The purpose of the study was to consider MRI hyperintensities as a potential endophenotype for bipolar disorder (BPD) and to investigate Notch3 (CADASIL) as a candidate gene for BPD. MRI scans were performed on 21 members of a family with a high incidence of BPD. Two-point and multipoint linkage analyses were performed and two exons of Notch3 were investigated with SSCP. Fifteen of 21 family members had MRI hyperintensities, including all bipolar patients and six family members with no affective illness. Two-point linkage analysis yielded negative results for all models. Multipoint linkage analysis yielded negative results except for Model 1a, in which a maximal LOD score was -1.24. A mutation screen of Exons 3 and 4 was negative. Notch3 does not appear to be a candidate gene for BPD in this family. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210282     DOI: 10.1002/ajmg.10512

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  13 in total

Review 1.  Hyperintense MRI lesions in bipolar disorder: A meta-analysis and review.

Authors:  John L Beyer; Robert Young; Maragatha Kuchibhatla; K Ranga R Krishnan
Journal:  Int Rev Psychiatry       Date:  2009

Review 2.  White matter hyperintensities: from medical comorbidities to bipolar disorders and back.

Authors:  Eva Gunde; Ryan Blagdon; Tomas Hajek
Journal:  Ann Med       Date:  2011-07-13       Impact factor: 4.709

Review 3.  Mapping vulnerability to bipolar disorder: a systematic review and meta-analysis of neuroimaging studies.

Authors:  Paolo Fusar-Poli; Oliver Howes; Andreas Bechdolf; Stefan Borgwardt
Journal:  J Psychiatry Neurosci       Date:  2012-05       Impact factor: 6.186

4.  Hippocampal morphology in lithium and non-lithium-treated bipolar I disorder patients, non-bipolar co-twins, and control twins.

Authors:  Theo G M van Erp; Paul M Thompson; Tuula Kieseppä; Carrie E Bearden; Alexandria C Marino; Gil D Hoftman; Jari Haukka; Timo Partonen; Matti Huttunen; Jaakko Kaprio; Jouko Lönnqvist; Veli-Pekka Poutanen; Arthur W Toga; Tyrone D Cannon
Journal:  Hum Brain Mapp       Date:  2011-03-31       Impact factor: 5.038

Review 5.  The endophenotype concept in psychiatric genetics.

Authors:  Jonathan Flint; Marcus R Munafò
Journal:  Psychol Med       Date:  2006-09-18       Impact factor: 7.723

6.  Relationship of cerebrospinal fluid glucose metabolites to MRI deep white matter hyperintensities and treatment resistance in bipolar disorder patients.

Authors:  William T Regenold; K Calvin Hisley; Pornima Phatak; Christopher M Marano; Abraham Obuchowski; David M Lefkowitz; Amritpal Sassan; Sameer Ohri; Tony L Phillips; Narveen Dosanjh; Robert R Conley; Rao Gullapalli
Journal:  Bipolar Disord       Date:  2008-11       Impact factor: 6.744

7.  Valproate activates the Notch3/c-FLIP signaling cascade: a strategy to attenuate white matter hyperintensities in bipolar disorder in late life?

Authors:  Peixiong Yuan; Giacomo Salvadore; Xiaoxia Li; Lei Zhang; Jing Du; Guang Chen; Husseini K Manji
Journal:  Bipolar Disord       Date:  2009-05       Impact factor: 6.744

Review 8.  Neuropsychiatric manifestations in CADASIL.

Authors:  Hugues Chabriat; Marie-Germaine Bousser
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

Review 9.  Frontotemporal White Matter in Adolescents with, and at-Risk for, Bipolar Disorder.

Authors:  Sonja M C de Zwarte; Jennifer A Y Johnston; Elizabeth T Cox Lippard; Hilary P Blumberg
Journal:  J Clin Med       Date:  2014-03-10       Impact factor: 4.241

10.  Bipolar II disorder as the initial presentation of CADASIL: an underdiagnosed manifestation.

Authors:  Jianjun Wang; Jinfang Li; Fanxin Kong; Hanqing Lv; Zhouke Guo
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-14       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.